 |
1 Product |  |
4 Diseases | | 1 Product |
|
0 Trials |  |
9 News |  |
- || mesenchymal stem cells (AC607) / AlloCure
Clinical, Journal, BRCA Biomarker: Human Endogenous Retrovirus Expression Is Upregulated in the Breast Cancer Microenvironment of HIV Infected Women: A Pilot Study. (Pubmed Central) - Nov 18, 2020
In addition, we found immune system, extracellular matrix organization and metabolic signaling genes upregulated in HIV-positive breast cancer. In conclusion, our findings provide evidence of transcriptional and retrotranscriptional changes in breast cancer from PLWH compared to non-HIV breast cancer, including dysregulation of HERVs, suggesting an indirect effect of the virus on the breast cancer microenvironment.
- | mesenchymal stem cells (AC607) / AlloCure
Journal: Allogeneic Mesenchymal Stem Cells for Treatment of AKI after Cardiac Surgery. (Pubmed Central) - Jul 17, 2019
In these patients with AKI after cardiac surgery, administration of allogeneic MSCs did not decrease the time to recovery of kidney function. Our results contrast with those in preclinical studies and provide important information regarding the potential effects of MSCs in this setting.
- | mesenchymal stem cells (AC607) / AlloCure
Enrollment change, Trial termination, Surgery: ACT-AKI: A Study to Evaluate the Safety and Efficacy of AC607 for the Treatment of Kidney Injury in Cardiac Surgery Subjects (clinicaltrials.gov) - Aug 6, 2014
P2, N=156, Terminated, Sponsor: AlloCure Inc.
Our results contrast with those in preclinical studies and provide important information regarding the potential effects of MSCs in this setting. N=200 --> 156 | Active, not recruiting --> Terminated
- || mesenchymal stem cells (AC607) / AlloCure
Trial completion date, Surgery: ACT-AKI: A Study to Evaluate the Safety and Efficacy of AC607 for the Treatment of Kidney Injury in Cardiac Surgery Subjects (clinicaltrials.gov) - May 4, 2014
P2, N=200, Active, not recruiting, Sponsor: AlloCure Inc.
N=200 --> 156 | Active, not recruiting --> Terminated Trial completion date: May 2017 --> Aug 2014
- || mesenchymal stem cells (AC607) / AlloCure
Trial primary completion date, Surgery: ACT-AKI: A Study to Evaluate the Safety and Efficacy of AC607 for the Treatment of Kidney Injury in Cardiac Surgery Subjects (clinicaltrials.gov) - May 4, 2014
P2, N=200, Active, not recruiting, Sponsor: AlloCure Inc.
Trial completion date: May 2017 --> Aug 2014 Trial primary completion date: Apr 2014 --> Aug 2014
- ||| mesenchymal stem cells (AC607) / AlloCure
Enrollment closed, Surgery: ACT-AKI: A Study to Evaluate the Safety and Efficacy of AC607 for the Treatment of Kidney Injury in Cardiac Surgery Subjects (clinicaltrials.gov) - May 4, 2014
P2, N=200, Active, not recruiting, Sponsor: AlloCure Inc.
Trial primary completion date: Apr 2014 --> Aug 2014 Recruiting --> Active, not recruiting
- |||| mesenchymal stem cells (AC607) / AlloCure
Enrollment open, Surgery: ACT-AKI: A Study to Evaluate the Safety and Efficacy of AC607 for the Treatment of Kidney Injury in Cardiac Surgery Subjects (clinicaltrials.gov) - Jun 28, 2012
P2, N=200, Recruiting, Sponsor: AlloCure Inc.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||| mesenchymal stem cells (AC607) / AlloCure
New P2 trial, Surgery: ACT-AKI: A Study to Evaluate the Safety and Efficacy of AC607 for the Treatment of Kidney Injury in Cardiac Surgery Subjects (clinicaltrials.gov) - May 17, 2012
P2, N=200, Recruiting, Sponsor: AlloCure Inc.